Topiramate for the treatment of methamphetamine addiction: a multi‐center placebo‐controlled trial

• DOI: 10.1111/j.1360-0443.2011.03771.x
• Publication Date: 2011-12-16T14:46:10Z
• Authors: Ahmed Elkashef; Roberta Kahn; Elmer Yu; Erin Iturriaga; Shou‐Hua Li; Ann Anderson; Nora Chiang; Nassima Ait‐Daoud; David Weiss; Frances McSherry; Tracey Serpi; Richard Rawson; Mark Hrymoc; Dennis Weis; Michael McCann; Tony Pham; Christopher Stock; Ruth Dickinson; Jan Campbell; Charles Gorodetzky; William Haning; Barry Carlton; Joseph Mawhinney; Ming D. Li; Bankole A. Johnson
• Keywords: Methamphetamine

ABSTRACT Aims Topiramate has shown efficacy at facilitating abstinence from alcohol and cocaine abuse. This double‐blind, placebo‐controlled out‐patient trial tested topiramate for treating methamphetamine addiction. Design Participants ( n = 140) were randomized to receive or placebo (13 weeks) in escalating doses 50 mg/day the target maintenance of 200 weeks 6–12 (tapered week 13). Medication was combined with weekly brief behavioral compliance enhancement treatment. Setting The conducted eight medical centers United States. One hundred forty methamphetamine‐dependent adults took part trial. Measurements primary outcome during 6–12. Secondary outcomes included use reduction versus baseline, as well psychosocial variables. Findings In intent‐to‐treat analysis, did not increase For secondary outcomes, reduced median urine levels observer‐rated severity dependence scores significantly. Subjects negative before randomization 26) had significantly greater on study safe tolerated. Conclusions does appear promote users but can reduce amount taken relapse rates those who are already abstinent.